Organisation paid for research Program year 2024 Source: CMS Open Payments

Investigative Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$435,485

43 payments

Through program year 2024, Investigative Clinical Research is reported as receiving $435,485 in research payments, across 43 payments.

By program year

6 rows

Year	Kind	Amount	Payments
2024	Research	$245	1
2023	Research	$13,405	3
2022	Research	$555	1
2021	Research	$9,929	11
2020	Research	$408,930	26
2019	Research	$2,420	1

Breakdown

Who paid Research payments · program years 2019–2024

Ironwood Pharmaceuticals, Inc $418,859 37 payments
Institut de Recherches Internationales Servier $13,405 3 payments
UCB Biosciences Inc. $2,420 1 payment
Apellis Pharmaceuticals, Inc. $800 2 payments

Studies the money was for Research payments · program years 2019–2024

C3718-302 $418,859 37 payments
Phase III Study of Trifluridine/Tipiracil in Combination With Bevacizumab VS Trifluridine/Tipiracil Single Agent in Patients With Refractory Metastatic Colorectal Cancer (Sunlight) $13,405 3 payments
A Non-Interventional, Long term, Post-Marketing Registry of Patients Treated with Certolizumab Pegol (CIMZIA) For Crohn's Disease $2,420 1 payment
Pegcetacoplan Long Term Safety and Efficacy Extension Study $555 1 payment
Pegcetacoplan Long Term Safety and Efficacy Extension Study $245 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.